8-K: Lifecore Biomedical Stockholders Approve Issuance Proposal at Special Meeting

Lifecore Biomedical stockholders approved the issuance of common stock underlying Series A Preferred Stock at a Special Meeting held on April 10, 2025.

Summary

• Lifecore Biomedical, Inc. held a Special Meeting of Stockholders on April 10, 2025.
• The record date for the Special Meeting was February 18, 2025.
• As of the record date, there were 37,025,331 shares of common stock and 44,894 shares of Series A Convertible Preferred Stock outstanding.
• Stockholders voted on two proposals: the Issuance Proposal and the Adjournment Proposal.
• The Issuance Proposal was to approve the issuance of common stock underlying shares of Series A Preferred Stock, exceeding 19.99% of outstanding common stock prior to the issuance of the Series A Preferred Stock.
• The Adjournment Proposal was to approve an adjournment of the Special Meeting to solicit additional proxies if there were not sufficient votes in favor of the Issuance Proposal.
• Stockholders approved the Issuance Proposal with 24,098,218 votes for, 444,639 votes against, and 33,281 abstentions.
• Stockholders also approved the Adjournment Proposal, but it was not necessary as the Issuance Proposal was approved.

Sentiment

Score: 7

Explanation: The document indicates a successful vote on a key proposal, suggesting positive progress for the company's plans. However, it's a procedural matter, so the sentiment is moderately positive.

Positives

• The approval of the Issuance Proposal allows Lifecore Biomedical to proceed with the issuance of common stock underlying the Series A Preferred Stock.
• The successful vote indicates shareholder support for the company's strategic direction.

Stakeholder Impact

• Shareholders: The approval of the Issuance Proposal may impact the value and dilution of existing shares.
• Company: The approval allows the company to proceed with its financing plans.

Key Dates

Keywords

Issuance Proposal, Special Meeting, Lifecore Biomedical, Stockholders, Common Stock, Series A Preferred Stock, Adjournment Proposal